|
|
||||||||
1 Department of Surgery, University of Michigan and Department of Veterans Affairs Medical Center, Ann Arbor, Michigan 48109; 2 First Department of Surgery, Yamaguchi University School of Medicine, Ube, 755-8505 Yamaguchi, Japan; and 3 Departments of Biomedical Engineering and Vascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio 44195
| |
ABSTRACT |
|---|
|
|
|---|
Smooth muscle cells (SMC) from prosthetic vascular grafts constitutively secrete higher levels of platelet-derived growth factor-AA (PDGF-AA) than aortic SMC. Lipid oxidation products accumulate in grafts and may stimulate PDGF production. The effect of oxidized low-density lipoprotein (oxLDL) on PDGF-AA secretion by aortic and graft SMC was compared. SMC isolated from canine thoracic aorta or Dacron thoracoabdominal grafts (n = 10) were incubated with native LDL or oxLDL (0-400 µg/ml) for 72 h. PDGF-AA in the conditioned medium was measured with enzyme-linked immunosorbent assay. OxLDL increased PDGF-AA production by graft SMC from 78 ± 2 to 256 ± 16 pg PDGF/µg DNA and aortic SMC from 21 ± 1 to 40 ± 2 pg PDGF/µg DNA. Native LDL had no effect. N-acetylcysteine inhibited oxLDL-induced PDGF increase. Both superoxide and H2O2 stimulated PDGF secretion by graft SMC had little effect on aortic SMC. Our results suggest that PDGF production by graft (synthetic) SMC is more sensitive to stimulation by oxidative stress than aortic (contractile) SMC. Lipid oxidation products that accumulate in prosthetic vascular grafts can cause an oxidative stress, which stimulates PDGF production by graft SMC. PDGF can induce migration of aortic SMC onto the graft, contributing to the development of intimal hyperplasia.
oxidative stress; reactive oxygen species; mitogen; phenotype; platelet-derived growth factor; smooth muscle cells; low-density lipoprotein
| |
INTRODUCTION |
|---|
|
|
|---|
INTIMAL HYPERPLASIA, characterized by smooth muscle cell (SMC) accumulation and matrix deposition, often develops after angioplasty or bypass grafting, and compromises the long-term patency of these interventions. The cause of anastomotic intimal hyperplasia is not known precisely, but mitogens released from platelets, leukocytes, endothelial cells (EC), and SMC may contribute to the initiation and perpetuation of the processes. SMC in intimal hyperplastic lesions of grafts are in a synthetic phenotype and produce high levels of platelet-derived growth factor (PDGF) (3, 15, 18, 23). Factors controlling SMC production of PDGF are unknown, but oxidized low-density lipoproteins (oxLDL) may play a role.
Elevated cholesterol is a well-recognized risk factor for angioplasty or vascular graft failure, just as it is for atherosclerosis. Oxidatively modified lipids and lipoproteins may play a role in vascular graft failure because lipid oxidation products accumulate in prosthetic grafts, and oxLDLs possess a number of properties that would adversely affect graft healing, including stimulation of SMC proliferation and extracellular matrix production. Our previous studies show that Dacron graft material can stimulate monocytic cells to oxidize LDL in vitro (29) and that products of lipid oxidation accumulate in prosthetic grafts in vivo (28). The exact relationship between accumulation of lipid oxidation products and the development of anastomotic intimal hyperplasia is currently unknown.
SMC cultured from prosthetic grafts produce higher levels of PDGF and collagen than do aortic SMC (19, 23). These phenotypic differences are maintained for several passages in culture. OxLDL is reported to stimulate PDGF A-chain transcripts in late passage human arterial SMC (26), so the ability of oxLDL to stimulate PDGF-AA production by graft and aortic SMC was studied. Graft SMC not only produced more PDGF than aortic SMC under basal conditions, but the graft SMC responded to oxLDL, superoxide generation, and H2O2 with a significantly greater increase in PDGF production than aortic SMC. N-acetylcysteine (NAC) blocked the stimulation of PDGF production by oxLDL. The elevated PDGF production may contribute to the development of anastomotic intimal hyperplasia by stimulating SMC migration and proliferation that eventually may cause synthetic vascular graft occlusion.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Graft implantation and removal. To evaluate PDGF production by SMC from the aorta and prosthetic vascular grafts, adult female mongrel dogs underwent placement of Cooley double-velour knitted Dacron thoracoabdominal grafts (Meadox Medicals). The grafts (8 mm internal diameter and 22 cm long) were implanted following the method described by Graham et al. (9). After 16-26 wk, the grafts and native vessels were carefully isolated from surrounding tissue and flushed with medium 199 (M199) tissue culture medium (Sigma). Tissue on the outer surface of the graft was removed during the harvest. The protocol for animal studies was approved by the institutional committee on animal use. All procedures and care complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 1996).
SMC harvest and culture.
Cells were harvested from the proximal aorta (ascending aorta and
aortic arch) and the distal abdominal aorta below the graft anastomosis. In addition, cells were isolated from midgraft sections. The luminal surface was incubated in collagenase A (630 U/ml; Boehringer-Mannheim) for 10 min at 37°C in a 5% CO2
atmosphere, and EC were removed mechanically. The medial layer of the
aorta was then stripped and the media and graft divided into 2 × 2 mm2 pieces. These pieces were incubated for 8 h at
room temperature with continuous gentle shaking in M199 that contained
15 U/ml elastase type III (Sigma), 170 U/ml collagenase A, 2 mg/ml
crystalline bovine serum albumin (Boehringer Mannheim), and 0.375 mg/ml
soybean trypsin inhibitor (Boehringer Mannheim). The SMC were collected with the use of a cell strainer (model HX86695, Falcon), resuspended in
M199, pelleted by centrifugation, plated in serum-coated tissue culture
plates, and grown to confluence in M199 with 20% fetal bovine serum
(FBS; Hyclone Laboratories), penicillin (100 U/ml), and streptomycin
(100 µg/ml). For all experiments, passage 2 or 3 SMC were plated in 24-well culture plates at 30,000 cells/cm2 and grown to confluence in M199 containing 20%
FBS at 37°C in a 5% CO2 atmosphere and then changed to
medium containing 5% FBS and the compound to be tested. The identity
and homogeneity of the SMC population were confirmed
immunohistochemically with antibody to SMC
-actin (Sigma).
Enzyme-linked immunosorption assay for canine PDGF-AA.
A heterogeneous sandwich assay was developed for quantifying PDGF-AA
production by canine SMC. Briefly, Nunc-immuno 96-well enzyme-linked
immunosorbent assay (ELISA) plates (MaxiSorp; Naperville, IL) were
coated with 50 µl of affinity purified polyclonal goat anti-human
PDGF-AA antibody (no. AD-221, R&D) at a dilution of 0.5 µg/ml of
coating buffer (0.6 M NaCl, 0.26 M H3BO4, and
0.08 N NaOH, pH 9.6) for 18 h at 4°C. After excess capture
antibody was removed and blocked with 3% bovine serum albumin and
phosphate-buffered saline for 120 min at 25°C, 100-µl aliquots of
recombinant human PDGF-AA (UBI) or samples were added and incubated for
18 h at 4°C. Detection antibody, polyclonal rabbit antihuman
PDGF-AA (Research Diagnostic), and 0.5 µg/ml blocking buffer was
added for 2 h at room temperature. Biotinylated anti-rabbit IgG
(BioGenex) (0.1 µg/well) was then added for 1 h. After being
washed, 0.1 µg/well streptaviden peroxidase (Sigma) was added for 45 min at room temperature in the dark. o-Phenylenediamine
(OPD) chromogenic substrate (DAKO) (100 µl/well) was added for 20 min, and the reaction was terminated with the addition of 100 µl/well
0.5 M H2SO4. The plates were read on an
ELISA plate scanner (model ELX 808, Bio-Tek Instruments) at 492 nm. The
detection limit for PDGF-AA was 20 pg/ml. ELISA was validated for
canine PDGF by measurement of serial dilutions from 1:1 to 1:16 of a
concentrated sample of conditioned medium. The curve that was generated
paralleled the standard, demonstrating reliable detection of canine
PDGF-AA over a range of 30-2,000 pg/ml (Fig.
1).
|
Protein synthesis assay. To measure protein synthesis, SMCs were incubated with [3H]leucine (0.5 mCi/ml, DuPont-NEN) and then harvested. [3H]Leucine that was incorporated into trichloroacetic acid (TCA; Sigma)-precipitable material was measured, as described by Fox and DiCorleto (8). Briefly, to measure secreted protein synthesis, the conditioned medium was collected and protein precipitated using chilled 5% TCA and 0.25% tannic acid. Cell-associated protein synthesis was determined by lysing the remaining cells and by precipitating protein with chilled 5% TCA-tannic acid solution. In both cases, the precipitate was solubilized with 0.5 N NaOH, neutralized with 50 µl 6 N HCl, and the radioactivity in each sample was then determined with a liquid-scintillation counter. Results were expressed as disintegrations per min per microgram of DNA.
DNA measurement. After the conditioned media were removed from the wells, cells were harvested and DNA quantitated using the method described by Labarca and Paigen (16). Briefly, cells were harvested by incubation in 0.05% trypsin solution and then lysed with a sonicator. The cell lysate (25 µl) was then diluted with phosphate/NaCl-buffered solution (4 M NaCl) and an equal volume of bis-benzimide solution (Sigma) added. Samples (200 µl) and DNA standards prepared with stock calf thymus DNA (Sigma) were added to 96-well plates (no. HX86610C, Costar) in triplicate. Plates were read on a Microplate Fluorescence Reader (model FL600, Bio-Tek Instruments) with excitation set at 360 nm and emission at 460 nm. The DNA standard curve was prepared and results were fit by nonlinear regression using the logistic equation.
LDL isolation and oxidation. Human LDL (density = 1.019-1.063 g/ml) was prepared by sequential ultracentrifugation of fresh, citrated plasma to which EDTA was added before centrifugation (11). Endotoxin was measured using a commercially available kit (Sigma). Cholesterol was measured using cholesterol calibrators (Sigma). Purified LDL was filtered through a 0.45-µm filter. LDL was stored in the dark at 4°C under nitrogen for no longer than 3 wk before use. Immediately before use, LDL was dialyzed at 4°C for 48 h against saline to remove the EDTA. For oxidization, LDL was diluted to 10 mg/ml in phosphate-buffered saline and incubated with 1.5 µM copper sulfate for ~18 h at 37°C until the clear solution became colorless. The level of LDL oxidation was monitored by the formation of thiobarbituric acid reacting substances (TBARS), measured by the method of Schuh and colleagues (25). Samples were analyzed by fluorimeter with excitation at 515 and emission at 553. TBARS were expressed as nanomoles of malondialdehyde (MDA) per milligram of cholesterol. The TBARS of oxLDL used in the experiments ranged from 5 to 8 nmol MDA/mg cholesterol, whereas TBARS for the native LDL ranged from 0.3 to 0.5 nmol MDA/mg cholesterol.
Reverse transcriptase-polymerase chain reaction. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to amplify the PDGF A-chain and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA isolated from the canine SMC. The primers used to amplify the PDGF A-chain were chosen based on previously published sequences (30). For canine GAPDH primers and probe were designed using a software program (Premier Biosoft International) and the cDNA sequence downloaded from a NCBI database (10). Oligonucleotides were synthesized commercially (Operon Technologies). The oligonucleotide sequences used for PDGF A-chain were as follows: sense primer (5'-CCT-GCC-CAT-TCG-GAG-GAA-GAG-3'), anti-sense primer (5'-TTG-GCC-ACC-TTG-ACG-CTG-CG-3'), and probe (5'-CGT-GCG-TGG-AGG-TGA-AAC-G-3') (30, 32). The corresponding sequences used for canine GAPDH were as follows: sense primer (5'-CAT-GTT-TGT-GAT-GGG-CGT-GAA-C-3'), anti-sense primer (5'-GTG-GCA-GTG-ATG-GCA-TGG-AC-3'), and probe (5'-TGG-ATG-ACT-TTG-CTA-GAG-G-3').
MRNA was extracted from SMC (3-5 × 106 SMC) using FastTrack version 2.0 kits (Invitrogen; San Diego, CA). Cells were lysed and the lysate applied to the oligo(dT)-cellulose column. After high- and low-salt buffer washes, mRNA was eluted from the column with a salt-free buffer. The mRNA products were dissolved in 5 µl of diethylpyrocarbonate-treated ddH2O and stored at
80°C
until use.
Complementary DNA (cDNA) was synthesized from the isolated mRNA using
Moloney murine leukemia virus RT, random hexamers, and deoxynucleotides. PDGF A-chain and GAPDH cDNA were then
selectively amplified in a thermal cycler using GeneAmp RNA PCR kits
(System 9600, Perkin-Elmer) with specific primers, excess nucleotide, and heat-stable DNA Taq polymerase. Amplification was
performed in the thermal cycler using 35 cycles with a denaturing
temperature of 94°C for 60 s, annealing temperature of 60°C
for 90 s, and an extension temperature of 72°C for 90 s.
The number of cycles was selected to remain in the linear phase of PCR
amplification. Ten microliters of the final PCR reaction mixtures were
applied on 2% agarose gel and visualized by ethidium bromide staining. Products of predicted size were detected and nonspecific bands were not
seen in the region of interest.
PCR-ELISA. After confirmation of the RT-PCR products as above, digoxigenin-labeled products were generated in subsequent studies. Ten microliters of 200 µM digoxigenin-labeled dNTP (Roche Molecular Biochemicals) was added to the PCR reaction mixture, RT-PCR was performed as described above, and products were detected by PCR-ELISA using a commercially available digoxigenin detection kit (Roche Molecular Biochemicals). Briefly, a digoxigenin-labeled amplified product was denatured for 10 min, and appropriate biotinylated probe was added in 500 µl of hybridization buffer. For negative controls, DNA was omitted or the inappropriate probe was used. Aliquots of 200 µl were added to duplicate wells of a streptavidin-coated 96-well plate and incubated for 4 h at 42°C. A bound product was detected with peroxidase-labeled anti-digoxigenin-peroxidase-conjugated antibody by standard colorimetric reaction with the use of the peroxidase substrate kit ABTS. An optical density at 405 nm was measured using a microplate reader. PDGF A-chain and GAPDH mRNA were amplified in parallel. Results were expressed as a ratio of the optical density for PDGF A-chain mRNA to the optical density for GAPDH. Northern blot analysis verified that GAPDH gene expression did not change during SMC incubation in oxLDL.
Statistics. All data represent means ± SE. Experiments were performed in triplicate with at least three different cell isolates. Data evaluation was performed by analysis of variance with the use of InStat (GraphPad Software) or t-test using Statview (BrainPower). Differences were considered statistically significant at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
In the present study, we explored the effect of oxLDL on PDGF-AA
secretion with aortic and graft SMC. Constitutive secretion of PDGF-AA
by graft SMC over 72 h was significantly higher than that by
aortic SMC at 78 ± 2 and 21 ± 3 pg PDGF/µg DNA,
respectively, P < 0.001 (Fig.
2). OxLDL (TBARS range of 5-8 nmol
MDA/mg cholesterol) induced a concentration-dependent increase in
PDGF-AA production by graft SMC, which was significantly greater than
aortic SMC. PDGF production was maximum at a concentration of 300 µg
cholesterol/ml, being 248 ± 21 and 37 ± 6 pg PDGF/µg DNA
for graft and aortic SMC, respectively. Native LDL (TBARS range of
0.3-0.5 nmol MDA/mg cholesterol) had no effect on graft or aortic
SMC PDGF production. The concentrations of oxLDL studied were not toxic
in 72 h as shown by stable levels of DNA and protein synthesis.
OxLDL induced a statistically significant increase in PDGF-AA
production by graft SMC (P < 0.001) but not by aortic
SMC.
|
OxLDL is known to produce an oxidative stress that might be responsible
for the increase in PDGF production. To determine the effect of other
oxidative stresses, PDGF production was measured after incubation of
graft and aortic SMC with H2O2 or
6-anilinoquinoline-5,8-quinone (LY-83583; Sigma), a substance known to
induce superoxide production by SMC (1). As with studies
using oxLDL, graft SMC were found to be much more responsive to the
stimulatory effects of LY-83583 or H2O2 than
were the aortic SMC. PDGF production by graft SMC increased from
66 ± 4 to 218 ± 6 pg PDGF/µg DNA (P < 0.001) as the LY-83583 concentration was increased from 0 to 1.2 µM
(Fig. 3). Over the same concentration
range, PDGF production by aortic SMC production rose from 23 ± 2 to 37 ± 3 pg PDGF/µg DNA (P > 0.05).
Similarly, as the H2O2 concentration was
increased from 0 to 50 µM, PDGF production by graft SMC increased
significantly from 73 ± 3 to 201 ± 9 pg PDGF/µg DNA
(P < 0.001), but PDGF production by aortic SMC was
relatively constant, changing from 19 ± 2 to 24 ± 2 pg
PDGF/µg DNA (P > 0.05) over the same
H2O2 concentration range (Fig.
4). At concentrations >50 µM,
decreases in DNA were noted in some experiments, suggesting toxicity.
These findings suggest that oxygen free radicals cause an increase in
SMC production of PDGF-AA and that graft SMC are more responsive to the
oxidative stress than aortic SMC.
|
|
The time course of the increase in graft SMC production of PDGF was
investigated. PDGF production in response to oxLDL,
H2O2, and LY-83583 was assessed at 24, 48, and
72 h. OxLDL, H2O2 and LY-83583 stimulated
an increase in PDGF-AA production compared with control, and the
increase was linear over time (Fig. 5).
|
Protein synthesis by graft and aortic SMC was measured to assess cell
viability and determine the specificity of changes in PDGF secretion
after incubation with agonists. SMC protein synthesis was determined in
conditions identical to those for PDGF assay. Confluent aortic and
graft SMC were incubated with oxLDL (300 µg/ml),
H2O2 (50 µM), or LY-83583 (1.5 µM).
[3H]leucine (0.5 mCi/ml) was added for determination of
protein synthesis. Both secreted and cell-associated protein synthesis was constant in control conditions and with all agonists studied (Fig.
6). This suggested that the stimulatory
effect of oxLDL, H2O2, and LY-83583 was
relatively specific for PDGF, and the increase in PDGF was not simply
part of a generalized increase in cellular protein synthesis. In
addition, agonists were not toxic in the concentrations used as
demonstrated by protein synthesis and visual morphologic analysis of
SMC.
|
The studies with oxLDL, H2O2, and LY-83583
suggest that reactive oxygen species (ROS) may alter PDGF production.
Therefore, the ability of antioxidants to prevent the increase in PDGF
production by graft SMC was evaluated. Several antioxidants, including
superoxide dismutase (SOD; 500 U/ml), catalase (4,000 U/ml), and NAC (1 mM) were tested for their effect on oxLDL-mediated increase in PDGF-AA production by graft SMC. SOD and catalase had no effect, even when
linked to polyethylene glycol (data not shown). This may have been due
to their relatively short duration of action. NAC blocked the increase
in PDGF secretion induced by oxLDL (Fig. 7). NAC was effective for concentrations
of oxLDL up to 400 µg cholesterol/ml. The ability of an intracellular
antioxidant to inhibit the increase in PDGF production suggests that
the oxidative stress created by oxLDL is at least in part responsible
for its effect on PDGF secretion.
|
The mechanism by which PDGF-AA production was increased was explored by
determining PDGF gene expression. Graft and aortic SMC were grown to
confluence and agonists added for 72 h. The conditioned medium was
removed for measurement of PDGF, and the cells were harvested for
isolation of mRNA. PDGF gene expression was determined using RT-PCR and
represented as the ratio of PDGF A-chain signal to GAPDH signal (Fig.
8). PDGF-AA production and mRNA
expression were increased in parallel by oxLDL,
H2O2, and LY-83583. OxLDL,
H2O2, and LY-83583 induced greater increases in
PDGF A-chain mRNA expression in graft SMC than in aortic cells. NAC
inhibited the oxLDL-induced increase in mRNA in graft SMC.
|
| |
DISCUSSION |
|---|
|
|
|---|
Intimal hyperplasia, which develops at the anastomoses of prosthetic vascular grafts and contributes to their failure, has many parallels to atherosclerosis. Graft implantation is accompanied by monocyte invasion, accumulation of lipid oxidation products, limited EC migration, and SMC proliferation (5, 28). This similarity in cellular dysfunction between vascular graft healing and atherosclerosis suggests that common factors may contribute to atherogenesis and graft failure. The lipid oxidation hypothesis of atherogenesis suggests that the cellular dysfunction occurs secondary to accumulation of oxidized lipids. Elevated cholesterol, a well-recognized risk factor for atherosclerosis, contributes to vascular graft failure (2, 4, 13). Interestingly, LDL is deposited preferentially at anastomoses of polytetrafluoroethylene grafts in rabbits (2, 20), the same regions that are susceptible to intimal thickening due to SMC proliferation and extracellular matrix accumulation. Lipid oxidation products that accumulate in grafts may contribute to the development of intimal hyperplasia by inducing changes in cellular function that would promote SMC accumulation.
OxLDL stimulates SMC proliferation and migration, and one mechanism may
involve increased PDGF production. Although previous studies have
suggested that oxLDL stimulates PDGF secretion (26, 33),
our results show that the constitutive production of PDGF by SMC, as
well as PDGF production in response to oxLDL,
H2O2, or LY-83583, is dependent on the
phenotype of the SMC. Contractile SMC from normal arteries produce a
little PDGF, but modified SMC from atherosclerotic lesions and
prosthetic grafts exhibit a synthetic phenotype and produce elevated
levels of PDGF (14, 17, 23). OxLDL, LY-83583, and
H2O2 have little effect on aortic SMC, but stimulate a marked increase in PDGF production by graft SMC. Zwijsen et
al. (33) found that exposure of the human umbilical artery SMC to LDL increased PDGF gene expression, as determined by in situ
hybridization. The effect was abrogated in the presence of BHT,
suggesting that oxidation products were responsible, but the LDL
oxidation that occurred during the 8-h incubation was not measured.
Stiko-Rahm et al. (26) found that a 1- to 4-h exposure to
Cu2+-oxidized LDL increased PDGF A-chain mRNA in late
passage (passages 8-16) human arterial SMC and
increased the expression of PDGF
- and
-receptors. In the
aforementioned studies the SMC would have expressed a synthetic or
undifferentiated phenotype, similar to graft SMC. Interestingly, we
found that oxLDL had no significant effect on PDGF production by early
passage (passage 2) aortic SMC that exhibited a more
differentiated, contractile phenotype, but did stimulate PDGF
production by late passage (>passage 6) aortic SMC after
they had undergone phenotypic modulation in culture (data not shown).
Changes in protein production paralleled changes in gene expression for
PDGF A-chain. Thus oxLDL stimulated PDGF production by SMC, but only
synthetic or dedifferentiated SMC, such as SMC in intimal hyperplastic
or atherosclerotic lesions. The ability of oxLDL to promote a
phenotypic transformation was not addressed in our study.
The mechanism by which oxLDL stimulates PDGF production may involve production of ROS. OxLDL induces superoxide production by SMC (12), and oxidative stress stimulates PDGF gene expression in EC in vitro and in lung in vivo (6, 22, 27). Furthermore, a lipid peroxidation product, 4-hydroxy-2-nonenal, induces PDGF-AA production and mitogenesis of rat SMC, the latter being inhibited by the antioxidant NAC (24). Our results support the role of ROS in the stimulation of PDGF production by oxLDL, because LY-83583, which stimulates superoxide production by NAD(P)H oxidases, and H2O2 increase PDGF production and gene expression by graft SMC. Furthermore, NAC abrogates the increase in PDGF production and gene expression induced by oxLDL. These findings support the premise that oxLDL stimulates PDGF production by causing an oxidative stress and increasing generation of ROS, which in turn increases PDGF gene expression and protein production. The stimulatory effect of oxLDL, LY-83583, and H2O2 on PDGF production by graft SMC but not aortic SMC suggests that graft SMC are more susceptible to oxidative stress. This could be the result of higher intrinsic ROS production by graft SMC or depleted antioxidant systems. West et al. (31) have shown that experimental vein grafts produce more superoxide than normal vein and that the principal source of the increased superoxide is NAD(P)H oxidase in the hyperplastic intimal SMC. This superoxide may be a mediator of graft intimal hyperplasia by stimulating production of PDGF and other mitogens, which in turn promote SMC migration and proliferation and contribute to intimal hyperplasia. Our results support this hypothesis, although our evidence for the role for free radicals is indirect, and the specific ROS potentially involved is not identified.
PDGF production in response to oxLDL could adversely impact on graft healing and contribute to the development of anastomotic intimal hyperplasia by stimulating SMC migration and proliferation. Ferns et al. (7) found that infusion of antibody to PDGF limited neointimal hyperplasia after rat carotid arterial injury by interfering with migration of medial SMC into the neointima. Previous studies in our laboratory showed that graft SMC produce high levels of PDGF (23) but suggested that PDGF production was not functioning in an autocrine fashion to stimulate SMC proliferation (21). Although graft SMC proliferated in response to PDGF, the response was blunted and fewer receptors were available for binding PDGF on graft SMC compared with aortic SMC. At the anastomosis, where lipid accumulation is the most concentrated, the PDGF-producing graft SMC are adjacent to PDGF-responsive arterial SMC. OxLDL-stimulated PDGF production may increase proliferation and migration of aortic SMC and contribute to the development of intimal hyperplasia in the anastomotic region. In addition, other factors, including the stimulation of extracellular matrix protein production by oxLDL, may promote the development of intimal lesions.
Our study shows that oxLDL consistently stimulates PDGF production by graft SMC that are in a secretory phenotype but has little effect on contractile aortic SMC production. Our observation that the origin (or phenotype) of the SMC is a determining factor in the response to oxLDL is a unique finding. Factors accounting for this observation, such as differences in antioxidant mechanisms or altered production of ROS by graft and aortic SMC, remain to be determined in future studies. An improved understanding of the effect of lipid oxidation products, which accumulate in prosthetic grafts, on the function of cells that migrate onto the grafts, will allow targeted interventions to improve cell function and graft patency.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by National Heart, Lung, and Blood Institute Grants HL-41178 and HL-64357 and by the Department of Veterans Affairs.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: L. M. Graham, Dept. of Biomedical Engineering/ND-20, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195 (E-mail: grahaml{at}ccf.org).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
April 11, 2002;10.1152/ajpheart.00060.2002
Received 23 January 2002; accepted in final form 9 April 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Baas, AS,
and
Berk BC.
Differential activation of mitogen-activated protein kinases by H2O2 and O
2.
Baumann, DS,
Doblas M,
Daugherty A,
Sicard G,
and
Schonfeld G.
The role of cholesterol accumulation in prosthetic vascular graft anastomotic intimal hyperplasia.
J Vasc Surg
19:
435-445,
1994[ISI][Medline].
3.
Birinyi, LK,
Warner SJC,
Salomon RN,
Callow AD,
and
Libby P.
Observations on human smooth muscle cell cultures from hyperplastic lesions of prosthetic bypass grafts: production of a platelet-derived growth factor-like mitogen and expression of a gene for a platelet-derived growth factor receptor. A preliminary study.
J Vasc Surg
10:
157-165,
1989[ISI][Medline].
4.
Campeau, L,
Enjalbert M,
Lespérance J,
Bourassa MG,
Kwiterovich P,
Wacholder S,
and
Sniderman A.
The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation.
N Engl J Med
311:
1329-1332,
1984[Abstract].
5.
De Bakey, ME,
Jordan GL,
Beall AC,
O'Neal RM,
Abbott JP,
and
Halpert B.
Basic biologic reactions to vascular grafts and prostheses.
Surg Clin North Am
45:
477-497,
1965[ISI][Medline].
6.
Fabisiak, JP,
Evans JN,
and
Kelley J.
Increased expression of PDGF-B (c-sis) mRNA in rat lung precedes DNA synthesis and tissue repair during chronic hyperoxia.
Am J Respir Cell Mol Biol
1:
181-189,
1989.
7.
Ferns, GAA,
Raines EW,
Sprugel KH,
Motani AS,
Reidy MA,
and
Ross R.
Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.
Science
253:
1129-1132,
1991
8.
Fox, PL,
and
DiCorleto PE.
Regulation of production of a platelet-derived growth factor-like protein by cultured bovine aortic endothelial cells.
J Cell Physiol
121:
298-308,
1984[ISI][Medline].
9.
Graham, LM,
Vinter DW,
Ford JW,
Kahn RH,
Burkel WE,
and
Stanley JC.
Endothelial cell seeding of prosthetic vascular grafts. Early experimental studies with cultured autologous canine endothelium.
Arch Surg
115:
929-933,
1980[Abstract].
10.
Gröne, A,
Weckmann MT,
Capen CC,
and
Rosol TJ.
Canine glyceraldehyde-3-phosphate dehydrogenase complementary DNA: polymerase chain reaction amplification, cloning, partial sequence analysis, and use as loading control in ribonuclease protection assays.
Am J Vet Res
57:
254-257,
1996[ISI][Medline].
11.
Hessler, JR,
Morel DW,
Lewis LJ,
and
Chisolm GM.
Lipoprotein oxidation and lipoprotein-induced cytotoxicity.
Arteriosclerosis
3:
215-222,
1983
12.
Hsieh, CC,
Yen MH,
Yen CH,
and
Lau YT.
Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells.
Cardiovasc Res
49:
135-145,
2001
13.
Klyachkin, ML,
Davies MG,
Svendsen E,
Kim JH,
Massey MF,
Barber L,
McCann RL,
and
Hagen PO.
Hypercholesterolemia and experimental vein grafts: accelerated development of intimal hyperplasia and an increase in abnormal vasomotor function.
J Surg Res
54:
451-468,
1993[ISI][Medline].
14.
Kraiss, LW,
Geary RL,
Mattsson EJR,
Vergel S,
Au YPT,
and
Clowes AW.
Acute reductions in blood flow and shear stress induce platelet-derived growth factor-A expression in baboon prosthetic grafts.
Circ Res
79:
45-53,
1996
15.
Kraiss, LW,
Raines EW,
Wilcox JN,
Seifert RA,
Barrett TB,
Kirkman TR,
Hart CE,
Bowen-Pope DF,
Ross R,
and
Clowes AW.
Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly.
J Clin Invest
92:
338-348,
1993[ISI][Medline].
16.
Labarca, C,
and
Paigen K.
A simple, rapid, and sensitive DNA assay procedure.
Anal Biochem
102:
344-352,
1980[ISI][Medline].
17.
Libby, P,
Warner SJC,
Salomon RN,
and
Birinyi LK.
Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma.
N Engl J Med
318:
1493-1498,
1988[Abstract].
18.
Margolin, DA,
Kaufman BR,
DeLuca DJ,
Fox PL,
and
Graham LM.
Increased platelet-derived growth factor production and intimal thickening during healing of Dacron grafts in a canine model.
J Vasc Surg
17:
858-867,
1993[ISI][Medline].
19.
Mesh, CL,
Majors A,
Mistele D,
Graham LM,
and
Ehrhart LA.
Graft smooth muscle cells specifically synthesize increased collagen.
J Vasc Surg
22:
142-149,
1995[ISI][Medline].
20.
Miller, A,
Schoen FJ,
Lees AM,
Fallon JT,
Strauss HW,
and
Lees RS.
Low density lipoprotein accumulation by PTFE grafts in the rabbit aorta. Autoradiographic-morphologic correlations.
ASAIO Trans
33:
489-493,
1987[Medline].
21.
Minion, DJ,
Van de Kerkhove MP,
Goodman GR,
van Aalst JA,
Absood A,
Fox PL,
and
Graham LM.
The proliferative response to platelet-derived growth factor of smooth muscle cells isolated from synthetic vascular grafts in a canine model.
J Vasc Surg
29:
845-850,
1999[ISI][Medline].
22.
Montisano, DF,
Mann T,
and
Spragg RG.
H2O2 increases expression of pulmonary artery endothelial cell platelet-derived growth factor mRNA.
J Appl Physiol
73:
2255-2262,
1992
23.
Pitsch, RJ,
Minion DJ,
Gorman ML,
van Aalst JA,
Fox PL,
and
Graham LM.
Platelet-derived growth factor production by cells from Dacron grafts implanted in a canine model.
J Vasc Surg
26:
70-78,
1997[ISI][Medline].
24.
Ruef, J,
Rao GN,
Li FZ,
Bode C,
Patterson C,
Bhatnagar A,
and
Runge MS.
Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal.
Circulation
97:
1071-1078,
1998
25.
Schuh, J,
Fairclough GF,
and
Haschemeyer RH.
Oxygen-mediated heterogeneity of apo-low-density lipoprotein.
Proc Natl Acad Sci USA
75:
3173-3177,
1978
26.
Stiko-Rahm, A,
Hultgårdh-Nilsson A,
Regnström J,
Hamsten A,
and
Nilsson J.
Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells.
Arterioscler Thromb
12:
1099-1109,
1992
27.
Tanswell, AK,
Han RN,
Buch SJ,
and
Fraher LJ.
Circulating factors that modify lung cell DNA synthesis following exposure to inhaled oxidants. III. Effects of plasma on lung pneumocyte and fibroblast DNA synthesis following exposure of adult rats to 85% oxygen.
Exp Lung Res
17:
869-886,
1991[ISI][Medline].
28.
van Aalst, JA,
Fox PL,
and
Graham LM.
Lipid oxidation products in implanted vascular grafts.
Surg Forum
49:
324-326,
1998.
29.
van Aalst, JA,
Pitsch RJ,
Absood A,
Fox PL,
and
Graham LM.
Mechanism of Dacron-activated monocytic cell oxidation of low density lipoprotein.
J Vasc Surg
31:
171-180,
2000[ISI][Medline].
30.
Wang, AM,
Doyle MV,
and
Mark DF.
Quantitation of mRNA by the polymerase chain reaction.
Proc Natl Acad Sci USA
86:
9717-9721,
1989
31.
West, NEJ,
Guzik TJ,
Black E,
and
Channon KM.
Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase.
Arterioscler Thromb Vasc Biol
21:
189-194,
2001
32.
Yamaguchi, M,
Du W,
Gould KE,
Dieffenbach CW,
Cruess DF,
and
Sharefkin JB.
Effects of aspirin, dipyridamole, and dibutyryl cyclic adenosine monophosphate on platelet-derived growth factor A chain mRNA levels in human saphenous vein endothelial cells and smooth muscle cells.
Surgery
110:
377-384,
1991[ISI][Medline].
33.
Zwijsen, RML,
Japenga SC,
Heijen AMP,
Van den Bos RC,
and
Koeman JH.
Induction of platelet-derived growth factor chain A gene expression in human smooth muscle cells by oxidized low density lipoproteins.
Biochem Biophys Res Commun
186:
1410-1416,
1992[ISI][Medline].
This article has been cited by other articles:
![]() |
J. L. Mehta Oxidized or Native Low-Density Lipoprotein Cholesterol: Which Is More Important in Atherogenesis? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 980 - 982. [Full Text] [PDF] |
||||
![]() |
A. Absood, A. Furutani, T. Kawamura, and L. M. Graham A comparison of oxidized LDL-induced collagen secretion by graft and aortic SMCs: role of PDGF Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1200 - H1206. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |